Current Neuro-Oncology

Volume 27 Number 16
10 June 2025

Home > Publications > Current Neuro-Oncology > Volume 27, Year 2025 > Number 16, 10 June

Bagley SJ, Desai AS, Fraietta JA, Silverbush D, Chafamo D, Freeburg NF, Gopikrishna GK, Rech AJ, Nabavizadeh A, Bagley LJ, Park J, Jarocha D, Martins R, Sarmiento N, Maloney E, Lledo L, Stein C, Marshall A, Leskowitz RM, Jadlowsky JK, Mackey S, Christensen S, Oner BS, Plesa G, Brennan A, Gonzalez V, Chen F, Barrett D, Colbourn R, Nasrallah MP, Mourelatos Z, Hwang WT, Alanio C, Siegel DL, June CH, Hexner EO, Binder ZA, O'Rourke DM.
Intracerebroventricular bivalent CAR T cells targeting EGFR and IL-13Rα2 in recurrent glioblastoma: a phase 1 trial.
Nat Med. 2025 Jun 1. doi: 10.1038/s41591-025-03745-0. PMID: 40451950. Interventional study. ˍ

*Dhingra S, Koshy M, Korpics M.
Limited survival benefit in patients diagnosed with glioblastoma post-2016: a SEER population based registry analysis.
J Cancer Res Clin Oncol. 2025 Jun 2;151(6):179. doi: 10.1007/s00432-025-06171-4. PMID: 40455099. Observational study. ˍ
>>> Tumor treating fields

Chen D, Le SB, Ghiaseddin AP, Manektalia H, Li M, O'Dell A, Rahman M, Tran DD.
Efficacy and safety of adjuvant TTFields plus pembrolizumab and temozolomide in newly diagnosed glioblastoma: A phase 2 study.
Med. 2025 Jun 3:100708. doi: 10.1016/j.medj.2025.100708. PMID: 40466642. Interventional study. ˍ

Kaes M, Rondinelli V, Krieg SM, Jakobs M.
The LITTability study - evaluation of the applicability of LITT in a real-world cohort of glioma patients.
Neurosurg Rev. 2025 Jun 3;48(1):477. doi: 10.1007/s10143-025-03644-5. PMID: 40457101. Observational study. ˍ

Marino S, Menna G, Doglietto F, Quaranta D, Chiesa S, Gaudino S, Russo R, Marziali G, Galeazzi M, D'Alessandris QG, Lauretti L, Mattogno PP, Di Bonaventura R, Caraglia N, Di Maio L, Olivi A, Della Pepa GM.
A white matter-centered approach to investigate recurrence pathways in high-grade gliomas: a single-center retrospective study.
J Neurooncol. 2025 Jun 3;174(1):177-190. doi: 10.1007/s11060-025-05050-9. PMID: 40459831. Observational study. ˍ

Deshors P, Kheil Z, Ligat L, Gouazé-Andersson V, Cohen-Jonathan Moyal E.
FGFR inhibition as a new therapeutic strategy to sensitize glioblastoma stem cells to tumor treating fields.
Cell Death Discov. 2025 Jun 4;11(1):265. doi: 10.1038/s41420-025-02542-5. PMID: 40467542. Laboratory investigation. ˍ

Zelba H, Shao B, Rabsteyn A, Reinhardt A, Greve C, Oenning L, Kayser S, Kyzirakos C, Latzer P, Riedlinger T, Bartsch O, Wünsche J, Harter J, Feldhahn M, Bantel Y, Johänning J, Ködding J, Hadaschik D, Schulze M, Battke F, Maksimovic O, Scheble V, Miller AM, Castro M, Blumenthal DT, Glas M, Reardon D, Biskup S.
In-depth characterization of vaccine-induced neoantigen-specific T cells in patients with IDH1-mutant glioma undergoing personalized peptide vaccination.
J Immunother Cancer. 2025 Jun 5;13(6):e011070. doi: 10.1136/jitc-2024-011070. PMID: 40480654. Translational study. ˍ

Kim MM, Lawrence TS, Cao Y.
Response-Adaptive Radiation Therapy: Toward Precision Radiation in Neuro-Oncology.
Int J Radiat Oncol Biol Phys. 2025 Juln 6;122(3):558-560. doi: 10.1016/j.ijrobp.2025.03.064. PMID: 40484469. Editorial˰ ˍ

Mazewski C, Leary SES, Kang G, Li BK, Kellie S, Hayes L, Shaw D, Ho B, Reddy A, Gossett J, Burger PC, Judkins AR, Aridgides P, Geyer JR, Gajjar A, Pollack IF, Fouladi M, Huang A.
Phase 3 randomized trial of high-dose methotrexate for young children with high-risk embryonal brain tumors: A report from the Children's Oncology Group.
Neuro Oncol. 2025 Jun 9:noaf132. doi: 10.1093/neuonc/noaf132. PMID: 40485042. Interventional study˰ ˍ